for males ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
completion around



The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Official Title

TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency


Metastatic Castration Resistant Prostate Cancer, CRPC, PARP inhibitor, PARPi, BRCA, ATM, HRD, TRITON, homologous recombination, DNA repair, DNA defect, DNA anomaly, germline, somatic, mCRPC, Prostatic Neoplasms, Docetaxel, Abiraterone Acetate, Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel


You can join if…

Open to males ages 18 years and up

  • Be 18 years old at the time the informed consent is signed
  • Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate that is metastatic
  • Be surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL (1.73 nM)
  • Be eligible for treatment with physician's choice of comparator treatment (abiraterone acetate, enzalutamide or docetaxel)
  • Experienced disease progression after having received 1 prior next generation androgen receptor-targeted therapy
  • Have a deleterious mutation in a BRCA1/2 or ATM gene

You CAN'T join if...

  • Active second malignancy, with the exception of curatively treated non melanoma skin cancer, carcinoma in situ, or superficial bladder cancer
  • Prior treatment with any PARP inhibitor
  • Prior treatment with chemotherapy for metastatic castration-resistant prostate cancer
  • Symptomatic and/or untreated central nervous system metastases
  • Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of study drug


  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco California 94158 United States
  • Pacific Hematology Oncology Associates
    San Francisco California 94115 United States
  • San Francisco VA Health Care System
    San Francisco California 94121 United States
  • Kaiser Permanente, Northern CA
    Vallejo California 94589 United States


in progress, not accepting new patients
Start Date
Completion Date
pharmaand GmbH
Phase 3 research study
Study Type
About 405 people participating
Last Updated